Abstract
Radical cystectomy with bilateral pelvic lymph node dissection is the standard of care for patients with clinically localized muscle-invasive bladder cancer. Survival after radical cystectomy is associated with final pathologic staging. Survival decreases with increasing pT stage because of the presence of occult micrometastases, indicating the need for systemic chemotherapy. Systemic chemotherapy is delivered as either neoadjuvant therapy preoperatively, or as adjuvant therapy postoperatively. This article reviews the evidence for neoadjuvant and adjuvant chemotherapy for the treatment of muscle-invasive bladder and upper tract urothelial cancer and offers recommendations based on these data and recently updated clinical guidelines.
Original language | English (US) |
---|---|
Pages (from-to) | 155-167 |
Number of pages | 13 |
Journal | Urologic Clinics of North America |
Volume | 45 |
Issue number | 2 |
DOIs | |
State | Published - May 2018 |
Keywords
- Adjuvant chemotherapy
- Bladder cancer
- Neoadjuvant chemotherapy
- Upper tract urothelial cancer
ASJC Scopus subject areas
- Urology